An Evaluation of Taletrectinib for the Treatment of ROS1+ Non-Small Cell Lung Cancer

Abstract

Introduction:

ROS1 fusion–positive non-small cell lung cancer (NSCLC) represents a rare but clinically important subset, occurring in 1–2% of patients and often associated with younger, never-smoker populations. Current first-generation tyrosine kinase inhibitors (TKIs) such as crizotinib and entrectinib provide meaningful benefit but are limited by poor central nervous system (CNS) penetration and the development of resistance mutations, particularly G2032R.

Areas covered:

This review evaluates the development, pharmacologic properties, and clinical outcomes of taletrectinib, a next-generation ROS1 inhibitor recently approved by the FDA. Taletrectinib demonstrated high objective response rates in both TKI-naïve (88.8%) and TKI-pretreated (55.8%) patients, including robust intracranial activity and efficacy against the G2032R mutation. The safety profile is favorable, with predominantly low-grade gastrointestinal and hepatic adverse events and minimal neurologic toxicity.

Expert opinion:

Taletrectinib addresses major limitations of earlier ROS1 inhibitors by combining systemic potency, CNS activity, and tolerability. While its approval represents a significant advance for ROS1+ NSCLC, challenges remain, including resistance mechanisms such as L2086F, limited global access, and the absence of phase III confirmatory trials. Ongoing research into sequencing strategies, resistance profiling, and novel combination regimens will be essential to optimize patient outcomes.

1. Introduction

ROS1 fusion–positive non-small cell lung cancer (NSCLC) accounts for approximately 1–2% of all NSCLC cases globally. Incidence may be slightly higher in selected populations, such as EGFR wild-type adenocarcinomas, with rates up to 4% reported in Taiwan. The disease is more common in younger, never-smoker patients with adenocarcinoma histology.[1][2][3][4][5]

Current treatment guidelines recommend first-line therapy with ROS1 TKIs. While crizotinib remains an option for first-line use, entrectinib is also approved and preferred for patients with CNS involvement due to superior brain penetration.[6][7][8] Next-generation TKIs such as repotrectinib and lorlatinib are considered for patients with resistance mutations (including G2032R) or CNS progression, although repotrectinib is FDA-approved for ROS1-positive NSCLC in the United States for both treatment naïve and pre-treated patients.[9] Chemotherapy is often reserved for patients who progress on TKIs or are ineligible for targeted therapy.[4] Regional variations exist: In China, crizotinib is most commonly used first-line, with increasing use of lorlatinib and ceritinib in later lines.[2] Access to next-generation TKIs and molecular diagnostics varies, impacting outcomes.[9]

Current unmet medical needs in ROS1 fusion–positive NSCLC include: (1) limited long-term efficacy of first-generation ROS1 tyrosine kinase inhibitors (TKIs) due to acquired resistance (notably the G2032R mutation), (2) suboptimal central nervous system (CNS) penetration leading to frequent brain metastases and CNS progression, and (3) restricted access to next-generation TKIs and comprehensive molecular profiling in some regions. Resistance develops in at least 50% of patients treated with crizotinib or entrectinib, and CNS progression is a major challenge. [2], [9], [10]

In ROS1 fusion–positive NSCLC, resistance to ROS1-targeted therapy can be broadly classified into on-target and off-target mechanisms [11]. On-target resistance involves secondary mutations within the ROS1 kinase domain that diminish drug binding. The most prevalent is the ROS1 G2032R solvent-front mutation, which introduces steric hindrance and confers resistance to first-generation inhibitors such as crizotinib, entrectinib, and lorlatinib, while retaining partial sensitivity to certain next-generation agents, including repotrectinib and cabozantinib [12][13]. Additional clinically relevant mutations include D2033N, S1986F/Y, L2026M, L2086F, L2155S, L2010M, G1957A, D1988N, and L1982V. Each of these alterations affects the kinase domain differently, leading to distinct shifts in inhibitor sensitivity profiles [14][15][16]. The specific mutation present often dictates which ROS1 inhibitor, if any, may remain clinically effective.

Off-target resistance occurs through activation of alternative oncogenic signaling pathways that bypass ROS1 dependency. Reported mechanisms include amplification of MET, activation of the EGFR pathway, and mutations in KRAS or other MAPK pathway components [17]. These alterations can drive tumor growth even in the absence of ROS1 kinase domain mutations, necessitating consideration of combination treatment strategies that target both ROS1 and the relevant bypass pathway. Additional resistance processes, such as epithelial-to-mesenchymal transition (EMT) and dysregulation of regulatory proteins like MIG6, can potentiate EGFR signaling and contribute to adaptive or acquired resistance [18][19].

Together, these on-target and off-target mechanisms highlight the need for ongoing molecular profiling at progression and the development of next-generation inhibitors and rational combination strategies to overcome therapeutic resistance in ROS1+ NSCLC.

2. Overview of the market:

Taletrectinib (brand name IBTROZI) is a selective, orally administered tyrosine kinase inhibitor (TKI) that substantially targets ROS1, including clinically significant resistance mutations such as G2032R, with weaker inhibition of the tropomyosin receptor kinases TRKA, TRKB, and TRKC. In ROS1 fusion–positive NSCLC, these fusion proteins drive oncogenesis by constitutively activating downstream signaling pathways, thereby promoting uncontrolled cellular proliferation. Taletrectinib blocks ROS1-mediated signaling, suppressing the growth of cancer cells harboring ROS1 fusions and resistance mutations. Preclinical models have demonstrated potent antitumor activity in both systemic and intracranial NSCLC, including in tumors with the G2032R mutation [20].

The development of taletrectinib has directly addressed several limitations of earlier generations of ROS1 inhibitors. Mechanistically, it is a highly potent, next-generation ROS1 TKI with strong central nervous system (CNS) penetration and sustained activity against major resistance mutations, particularly the G2032R solvent-front mutation—a common cause of acquired resistance to first-generation inhibitors such as crizotinib and entrectinib. Furthermore, taletrectinib is designed to limit TRKB inhibition, thereby reducing the incidence of neurologic adverse events that have limited the tolerability of other ROS1 inhibitors [21].

The recent FDA approval of taletrectinib represents a significant milestone in the management of ROS1 fusion–positive NSCLC, as it offers a potent, CNS-active, and well-tolerated therapeutic option that addresses the principal clinical challenges associated with earlier ROS1-targeted agents [10].

3. Introduction to the drug: Chemistry, Pharmacodynamics, and Pharmacokinetics

Taletrectinib is a kinase inhibitor formulated as taletrectinib adipate. Structurally, it is an imidazo[1,2-b]pyridazine derivative specifically engineered to optimize binding affinity for the ATP-binding pocket of ROS1, including clinically significant resistance mutations such as G2032R, which confer resistance to first-generation ROS1 inhibitors like crizotinib [20].

The molecule possesses defined (R) stereochemistry at two chiral centers, a feature essential for its target selectivity and pharmacodynamic profile. This structural configuration minimizes off-target inhibition of TRKB, thereby reducing the incidence of neurologic adverse events that are more common with other ROS1/NTRK inhibitors. The compound’s design thus balances high potency against ROS1 with improved tolerability [22].

Taletrectinib is administered orally at a recommended dose of 600 mg once daily on an empty stomach. Following administration, the drug is rapidly absorbed, with peak plasma concentrations (Tmax) reached within 2–6 hours. Systemic exposure, measured as area under the curve (AUC) and maximum concentration (Cmax), increases proportionally with dose. Steady-state concentrations are typically achieved within 7 days, with approximately fourfold drug accumulation. Co-administration with a high-fat meal increases both AUC and Cmax by ~1.5-fold. The apparent oral volume of distribution is 9,820 L, indicating extensive tissue distribution. Plasma protein binding is high and concentration-dependent, ranging from 93% to 96% [20][21][23][24].

These pharmacokinetic characteristics, combined with CNS penetration and mutation-targeted design, underpin taletrectinib’s efficacy in both systemic and intracranial disease settings.

4. Preclinical Studies

Preclinical investigations have demonstrated that taletrectinib possesses potent activity against ROS1-driven malignancies, including those with clinically relevant resistance mutations. In vitro, taletrectinib effectively inhibits the proliferation of cancer cell lines harboring ROS1 fusions as well as those with secondary resistance mutations, most notably G2032R. In vivo, the drug significantly suppresses tumor growth in mouse xenograft models of ROS1 fusion–positive cancers, including models with the G2032R mutation. Importantly, taletrectinib exhibits substantial central nervous system penetration and antitumor activity in intracranial NSCLC xenograft models, supporting its potential in the treatment of brain metastases [24][25][21]. Nonclinical toxicology studies found that taletrectinib was not mutagenic or clastogenic in standard assays, and did not impair fertility in rats at exposures up to those achieved in humans at the recommended dose. Sperm morphological abnormalities were observed at exposures below the human equivalent, but without effects on mating or fertility [57].

5. Clinical Efficacy (Phase I, II, III studies)

The clinical efficacy of taletrectinib in ROS1 fusion-positive NSCLC has been primarily characterized through early-phase clinical trials. Initial evidence stems from a first-in-human, dose-escalation phase I study involving patients with advanced solid tumors, including those with ROS1-positive NSCLC. Taletrectinib was administered at doses ranging from 50 mg to 1,200 mg once daily or 400 mg twice daily, with the maximum tolerated dose (MTD) established at 800 mg once daily. [42]

In the cohort of crizotinib-refractory ROS1+ NSCLC patients evaluable per RECIST criteria, the confirmed objective response rate (ORR) was 33.3% (2/6 patients). Additionally, a patient with differentiated thyroid cancer achieved a confirmed partial response sustained for 27 months.

Clinical benefit was also reflected by reductions in pain scores within the 800 mg once-daily cohort. Treatment-related adverse events were predominantly gastrointestinal (nausea, diarrhea, vomiting) and elevations in liver transaminases, with dose-limiting toxicities manifesting as grade 3 transaminase elevations at the highest dose level. [55][42] These findings indicate that taletrectinib has a manageable safety profile at the MTD and exhibits preliminary antitumor activity in ROS1+ NSCLC, including in patients previously exposed to crizotinib.

A subsequent phase I study combined data from trials conducted in the United States and Japan to evaluate taletrectinib efficacy in advanced ROS1 fusion-positive NSCLC. Among ROS1 TKI-naïve patients, the confirmed ORR was 66.7% (95% CI: 35.4–87.9), with a disease control rate of 100%. In crizotinib-pretreated patients, the confirmed ORR was 33.3% (95% CI: 9.7–70.0), and the disease control rate was 88.3%. Median progression-free survival (PFS) was 29.1 months for TKI-naïve patients and 14.2 months for those refractory to crizotinib. The most common treatment-related adverse events were elevations in alanine and aspartate transaminases (each observed in 72.7% of patients), nausea (50%), and diarrhea (50%). Grade ≥3 adverse events included alanine transaminase elevation (18.2%), aspartate transaminase elevation (9.1%), and diarrhea (4.5%).[43] These data underscore taletrectinib’s meaningful clinical activity in both TKI-naïve and crizotinib-refractory ROS1+ NSCLC, coupled with a manageable safety profile.

The most recent phase II efficacy data derive from a pooled analysis of the TRUST-I (NCT04395677) and TRUST-II (NCT04919811) studies—multicenter, single-arm, open-label phase II trials enrolling patients with locally advanced or metastatic ROS1-positive NSCLC. TRUST-II, currently recruiting across North America, Europe, and Asia, includes multiple cohorts for both TKI-naïve and TKI-pretreated patients, as well as other ROS1-positive solid tumors. These trials evaluated taletrectinib 600 mg orally once daily. In the pooled efficacy-evaluable population (n=273), the confirmed objective response rate (cORR) was 88.8% among TKI-naïve patients and 55.8% among TKI-pretreated patients. Intracranial efficacy was notable, with intracranial cORRs of 76.5% and 65.6% in TKI-naïve and TKI-pretreated patients, respectively. Responses were durable: median duration of response (DOR) and PFS in TKI-naïve patients were 44.2 and 45.6 months, respectively; in TKI-pretreated patients, median DOR and PFS were 16.6 and 9.7 months. Importantly, among patients harboring the ROS1 G2032R resistance mutation, cORR was 61.5%.[56][26]

Table 1 summarizes the available phase I and II trial results for taletrectinib in ROS1-positive NSCLC. As of September 2025, there are no published phase III trial results for taletrectinib. The pivotal efficacy and safety data supporting regulatory approval are derived from phase II studies (TRUST-I and TRUST-II).

Table 1:

Summary of available trial results for taletrectinib in ROS1-positive NSCLC

Study/Phase	Population/Setting	Dose & Schedule	Efficacy: ORR (%)	Efficacy: Intracranial ORR (%)	Median DOR (months)	Median PFS (months)	Key Safety Findings	References
Phase I (Papadopoulos et al., 2020)	Advanced solid tumors (incl. crizotinib-refractory ROS1+ NSCLC)	50–1,200 mg QD or 400 mg BID; MTD 800 mg QD	33.3% (crizotinib-refractory ROS1+ NSCLC)	Not reported	Not reported	Not reported	GI AEs (nausea 47.8%, diarrhea 43.5%, vomiting 32.6%), grade 3 transaminase ↑ at highest dose	[1–2][42]
Phase II TRUST-I (Li et al., 2024)	Chinese ROS1+ NSCLC; TKI-naïve (n=106), crizotinib-pretreated (n=67)	600 mg QD, fasting	91% (TKI-naïve), 52% (crizotinib-pretreated)	88% (TKI-naïve), 73% (crizotinib-pretreated)	NR (TKI-naïve), 10.6 (crizotinib-pretreated)	NR (TKI-naïve), 7.6 (crizotinib-pretreated)	AST ↑ (76%), diarrhea (70%), ALT ↑ (68%), mostly grade 1–2; low neurologic AEs	[2–3][26]
Phase II TRUST-II (Pérol et al., 2025; FDA, 2025)	Global ROS1+ NSCLC; TKI-naïve (n=54), TKI-pretreated (n=47)	600 mg QD, fasting	85% (TKI-naïve), 62% (TKI-pretreated)	63% (TKI-naïve), 65.6% (TKI-pretreated)	NR (TKI-naïve), 16.6 (TKI-pretreated)	NR (TKI-naïve), 9.7 (TKI-pretreated)	GI AEs (88%), AST ↑ (72%), ALT ↑ (68%), mostly grade 1; low neurologic AEs	[4–5][56]
Pooled Phase II (Pérol et al., 2025; FDA, 2025)	Combined TRUST-I/II; TKI-naïve (n=160), TKI-pretreated (n=113)	600 mg QD, fasting	88.8% (TKI-naïve), 55.8% (TKI-pretreated)	76.5% (TKI-naïve), 65.6% (TKI-pretreated)	44.2 (TKI-naïve), 16.6 (TKI-pretreated)	45.6 (TKI-naïve), 9.7 (TKI-pretreated)	GI AEs (88%), AST ↑ (72%), ALT ↑ (68%), mostly grade 1; low neurologic AEs	[4–5][12], [56]
G2032R mutation (Pérol et al., 2025; Li et al., 2024)	ROS1+ NSCLC with G2032R	600 mg QD, fasting	61.5–67%	Not reported	Not reported	Not reported	Similar safety profile	[3–4][22], [56]

Key:

• ORR: Objective Response Rate
• DOR: Duration of Response
• PFS: Progression-Free Survival
• GI AEs: Gastrointestinal Adverse Events
• AST/ALT ↑: Increased transaminases
• NR: Not reached at data cutoff
• QD: Once daily
• BID: Twice daily

In conclusion, taletrectinib demonstrates robust and durable systemic as well as intracranial efficacy in ROS1+ NSCLC, including in patients with acquired resistance mutations.

6. Post-marketing surveillance:

Safety and tolerability data for taletrectinib in ROS1 fusion–positive non-small cell lung cancer have been reported from the phase I study and the phase II TRUST-I and TRUST-II trials. In the phase I trial, the most common treatment-related adverse events were gastrointestinal (nausea 47.8%, diarrhea 43.5%, vomiting 32.6%), with dose-limiting toxicities of grade 3 transaminase elevations at the highest dose; the maximum tolerated dose was 800 mg once daily. Most adverse events were grade 1–2, and no unexpected safety signals were observed.[42]

In the phase II TRUST-I study, the most frequent treatment-emergent adverse events were increased AST (76%), diarrhea (70%), and increased ALT (68%), with most being grade 1–2. Neurologic adverse events were infrequent and mild (dizziness 23%, dysgeusia 10%, both mostly grade 1). Discontinuation due to adverse events occurred in 5% of patients, and dose reductions were required in 19%.[56] The phase II TRUST-II study and pooled analyses confirmed this safety profile: among 352 patients treated at the recommended dose (600 mg once daily), gastrointestinal events (88%) and elevated AST (72%) and ALT (68%) were most common, again predominantly grade 1. Neurologic adverse events remained infrequent (dizziness 21%, dysgeusia 15%, mostly grade 1). The rate of discontinuation due to adverse events was 6.5%.[23], [26]

Serious adverse events such as hepatotoxicity, interstitial lung disease/pneumonitis, QTc prolongation, hyperuricemia, myalgia with CPK elevation, and skeletal fractures are rare but are included in the FDA warnings and precautions.[4], [40] Overall, taletrectinib demonstrates a favorable safety and tolerability profile, with low rates of severe or neurologic toxicity in both TKI-naïve and TKI-pretreated ROS1+ NSCLC.

Comparative review of other TKIs show that crizotinib is generally well tolerated, with most adverse events being grade 1–2 (visual disturbances, GI symptoms, mild transaminase elevations), but it is associated with a higher rate of grade 3/4 adverse events (18.7%) and lacks CNS penetration, which can lead to CNS progression.[8], [9] Entrectinib has a higher incidence of neurologic adverse events (dizziness, dysgeusia, cognitive changes), fatigue, and weight gain, with grade 3/4 adverse events occurring in 34% of patients. CNS-related side effects are more common than with taletrectinib.[3], [17], [47] Lorlatinib is notable for frequent hyperlipidemia (hypertriglyceridemia 19%, hypercholesterolemia 14%), CNS effects (cognitive and mood changes), and peripheral edema. Grade 3/4 adverse events occur in 39% of patients, and dose modifications are often required. [6], [35], [54] A recent meta-analysis confirms that taletrectinib and repotrectinib are associated with lower rates of serious adverse events compared to crizotinib, entrectinib, and lorlatinib, with taletrectinib particularly notable for its low incidence of neurologic toxicity and manageable hepatotoxicity. [5] These findings support the use of taletrectinib as a well-tolerated option for ROS1+ NSCLC, especially in patients at risk for CNS toxicity or with prior TKI intolerance.

7. Regulatory affairs

Taletrectinib is currently approved in the United States for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).[11] The FDA granted approval for this indication on June 11, 2025, under the brand name Ibtrozi, based on efficacy and safety data from the TRUST-I and TRUST-II clinical trials. The recommended dosage is 600 mg orally once daily on an empty stomach, continued until disease progression or unacceptable toxicity. [4], [12], [40]

As of September 2025, taletrectinib is not yet approved in Europe or other major regions such as Japan, Canada, or China for ROS1-positive NSCLC. However, global phase II trials (TRUST-II) are ongoing and have completed enrollment in North America, Europe, and Asia, and regulatory submissions are anticipated in these regions. The current approved indication is strictly for adult patients with locally advanced or metastatic ROS1-positive NSCLC, and there are no other approved indications at this time.[23], [24], [55]

Post-Progression Strategies

Patients with ROS1 fusion-positive NSCLC who experience disease progression following taletrectinib treatment will likely encounter a complex therapeutic landscape influenced by diverse resistance mechanisms and the availability of subsequent targeted therapies. Notably, the ROS1 L2086F mutation, localized within the central β-sheet 6 (Cβ6) region of the kinase domain, confers acquired resistance by inducing conformational changes that reduce inhibitor binding affinity. This mutation is implicated in resistance not only to taletrectinib but also to other next-generation ROS1 TKIs such as repotrectinib [27][41].

Comprehensive reviews of ROS1 TKI resistance further emphasize that although taletrectinib was designed to overcome common on-target resistance mutations like G2032R, the emergence of rarer mutations such as L2086F poses new clinical challenges. These insights highlight the critical importance of repeat molecular profiling upon disease progression, facilitating precision therapeutic decision-making. Clinical guideline bodies, including the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology, and the American Society of Clinical Oncology, specifically recommend RNA-NGS as the preferred or criterion standard method for fusion detection in NSCLC, including ROS1, due to its superior sensitivity and specificity for actionable fusions and splicing variants. RNA-NGS also enables detection of resistance mutations that manifest as alternative splicing or novel fusion partners, which may be missed by DNA-based approaches.[1][23][42]

Among next-line targeted therapies, repotrectinib—a CNS-penetrant, next-generation ROS1 inhibitor with FDA approval for locally advanced or metastatic ROS1-positive NSCLC—has demonstrated significant efficacy in patients previously treated with ROS1 TKIs. Repotrectinib achieves objective response rates ranging from 38% to 59% in TKI-pretreated populations, including robust activity against the G2032R solvent-front mutation, with durable systemic and intracranial responses. Given the spectrum of coverage against ROS1 between repotrectinib and taletrectinib are similar, it can be argued that repotrectinib is unlikely to work after progression on taletrectinib. However, it can still be used as an appropriate replacement especially when taletrectinib is not tolerated well due to toxicities and vice versa; taletrectinib may be considered if repotrectinib is not well tolerated [7][30][38]. Although “off-label”, lorlatinib represents another potential therapeutic option for patients progressing after first-generation ROS1 TKIs, exhibiting activity in crizotinib-refractory and TKI-pretreated patients, including those with central nervous system involvement.[35]

Patients harboring the ROS1 L2086F resistance mutation have a few treatment options. The L2086F mutation in the central β-sheet 6 (Cβ6) region mediates resistance through a mechanism distinct from the solvent-front G2032R alteration, rendering type I TKIs—crizotinib, entrectinib, taletrectinib, lorlatinib, and repotrectinib, all of which bind the DFG-in conformation—uniformly ineffective, whereas type II TKIs adopt a DFG-out configuration that circumvents the steric hindrance imposed by L2086F. Cabozantinib and merestinib retain potent activity against L2086F in preclinical models, with structural analyses showing that cabozantinib’s quinolone-based scaffold enables a DFG-out pose that accommodates this mutation. Gilteritinib, a type I FLT3 inhibitor with a pyrazine carboxamide scaffold, uniquely inhibits both wild-type and L2086F ROS1 via a distinct DFG-in binding mode, yet remains inactive against G2032R, highlighting the lack of a single agent capable of overcoming both resistance mechanisms. Although cabozantinib and gilteritinib suppress L2086F, their multi-kinase inhibition profiles contribute to off-target toxicities, and no prospective clinical trials have tested them specifically in ROS1 L2086F-positive NSCLC. As no current TKIs are designed to simultaneously target solvent-front and Cβ6 mutations, the development of next-generation inhibitors with dual activity and improved selectivity remains an urgent priority for advancing therapy in ROS1-positive NSCLC [21].

Emerging agents such as zidesamtinib and foritinib have also exhibited promising efficacy in patients pretreated with other ROS1 TKIs, including those with brain metastases. Zidesamtinib is a ROS1-selective macrocyclic tyrosine kinase inhibitor designed to overcome two major challenges—resistance mutations, especially the prevalent ROS1 G2032R substitution, and off-target TRK inhibition that drives neurological toxicities—its macrocyclic structure enabling unique accommodation of G2032R while sterically disfavoring TRK binding. In accelerated mutagenesis screens, it inhibited more than 1,500 pooled ROS1 mutants at clinically relevant concentrations with ≤1% resistance emergence, outperforming crizotinib, entrectinib, and repotrectinib, and in intracranial G2032R xenograft models it produced more durable responses than repotrectinib or taletrectinib. Foritinib (formerly SAF-189s), a next-generation ALK/ROS1 inhibitor with sub-nanomolar to nanomolar potency against wild-type and mutant ROS1—including G2032R—demonstrates CNS penetration, robust antitumor activity in xenografts, and clinically meaningful systemic and intracranial responses in Chinese patients with advanced ROS1-rearranged NSCLC who had progressed on crizotinib. Notably, zidesamtinib retains activity after next-generation ROS1 TKI failure, achieving ORRs of 47% and 43% in repotrectinib- and taletrectinib-pretreated patients, respectively, while its TRK-sparing design may reduce neurologic toxicity and improve sequential tolerability. Complementing this, foritinib achieved a 40% ORR—including a 40% intracranial ORR—in ROS1 inhibitor-pretreated patients and strikingly high response rates in inhibitor-naïve individuals (88–94% ORR; 90–100% intracranial ORR), highlighting its potential both as a post-TKI option and a promising future first-line therapy [36–37][58].

8. Conclusion

Taletrectinib has shown high and durable efficacy in ROS1-positive NSCLC, with objective response rates of 88.8% in TKI-naïve and 55.8% in TKI-pretreated patients, alongside robust intracranial activity. It retains potency against the G2032R resistance mutation and demonstrates a favorable safety profile, with mainly mild gastrointestinal and reversible hepatic events, and low neurologic toxicity. At the recommended dose of 600 mg once daily, taletrectinib offers a potent, CNS-active, and well-tolerated therapy that addresses key limitations of earlier ROS1 inhibitors and marks a significant advance in precision oncology for lung cancer.

9. Expert Opinion

The recent FDA approval of taletrectinib for ROS1 fusion-positive NSCLC represents a significant advancement in the management of this rare molecular subset. This approval addresses key unmet clinical needs that remain with first-generation ROS1 inhibitors such as crizotinib and entrectinib, which are hampered by limited CNS activity and susceptibility to resistance mutations. Clinicians anticipate that taletrectinib will establish itself as a preferred agent both in the first-line setting and for subsequent therapy in patients with ROS1+ NSCLC, particularly those presenting with brain metastases or acquired resistance to earlier TKIs [10][23].

Nevertheless, pivotal studies supporting taletrectinib’s approval—namely TRUST-I and TRUST-II—are subject to notable limitations. Both trials employed a single-arm, open-label, nonrandomized design, which precludes direct comparison with standard-of-care therapies and introduces potential selection and assessment biases. The absence of a randomized control group limits the ability to conclusively attribute observed efficacy and safety outcomes solely to taletrectinib and may lead to overestimation of benefit. Furthermore, the enrolled populations were highly selected, consisting predominantly of patients with ECOG performance status 0–1 and measurable disease, which may not fully represent the heterogeneity of the real-world ROS1+ NSCLC population—including those with poorer functional status or significant comorbidities. Diagnostic heterogeneity was also introduced by reliance on local laboratory methods for ROS1 fusion detection, raising concerns regarding diagnostic accuracy and potential misclassification. Although follow-up durations were substantial, they remain insufficient to fully characterize long-term outcomes such as overall survival and late toxicities—especially in TKI-naïve cohorts, where median duration of response and progression-free survival had not yet been reached at the time of analysis. Subgroup analyses, including those focused on patients harboring resistance mutations like G2032R, were constrained by small sample sizes, limiting statistical power and generalizability. Additionally, the studies did not systematically investigate mechanisms of resistance emerging during taletrectinib therapy nor did they evaluate sequencing strategies involving other ROS1 inhibitors or combination regimens, leaving critical questions regarding optimal post-progression on next generation ROS1 TKI management unanswered [55][27] [23].

In the absence of direct comparative head-to-head trials in TKI-naive patients with ROS1+ NSCLC, Nagasaka and colleagues recently employed a matching-adjusted indirect comparison (MAIC) to evaluate taletrectinib against the first-generation TKIs crizotinib and entrectinib. This statistical approach re-weights individual patient data from the taletrectinib cohort to match the baseline characteristics of patients in studies of crizotinib and entrectinib, for which only aggregate data are available. In this cross-trial analysis, taletrectinib was associated with a notably higher objective response rate—approximately 20% greater than either comparator—and demonstrated a statistically significant reduction in the risk of disease progression or death (by 52% versus crizotinib and 58% versus entrectinib), as well as a significant reduction in the risk of death (by 66% and 52%, respectively) compared to crizotinib and entrectinib. Importantly, the overall safety profile of taletrectinib was similar to that of the first-generation TKIs, with comparable rates of grade 3 treatment-related adverse events across all agents [24][25].

In the United States currently, no phase III clinical trials evaluating taletrectinib in ROS1 fusion-positive NSCLC are ongoing. This gap may reflect ethical and practical challenges, including clinician reluctance to randomize patients given taletrectinib’s demonstrated potency and the perceived inferiority of existing standard therapies. Such factors contribute to slow accrual rates, particularly in a rare molecular subset such as ROS1+ NSCLC and may disincentivize pharmaceutical investment in further large-scale trials. However, NCT06564324, a phase III randomized study comparing taletrectinib with standard therapy in ROS1+ NSCLC is ongoing in China and has started recruiting [20]. The questions remains whether it is ethical to do these “confirmatory” studies in China or regions in the world where access to TKIs might be limited. While patient cohorts remain small, there is growing advocacy for tumor-agnostic regulatory approvals for agents targeting rare molecular alterations such as ROS1 fusions.

A clinician-oriented framework for sequencing therapies after taletrectinib failure in ROS1-positive NSCLC should be guided by molecular profiling to identify specific resistance mutations, with treatment choices based on mutation type and drug availability. For L2086F, type I TKIs are ineffective; cabozantinib, a type II TKI, is would be the preferred option, though it remains off-label. Gilteritinib may offer activity against L2086F but not G2032R.

If no clear on-target resistance mutations are identified, a switch to or the addition of chemotherapy to the ROS1 TKI in use may be considered in systemic treatment failure while local consolidative therapy (such as focused radiation or surgery) may be used in cases of localized treatment failure.

There is an unmet need for agents that target both G2032R and L2086F mutations, and ongoing research is focused on improving treatment strategies and developing more selective and tolerable therapies [21][41].

Looking forward, key priorities include optimizing sequencing strategies for ROS1 inhibitors, developing novel agents capable of overcoming emergent resistance mutations such as L2086F, and exploring combination approaches to prevent or delay resistance development. Parallel efforts to enhance diagnostic accuracy through RNA-based next-generation sequencing are crucial to ensure precise patient selection for targeted therapy. Continued research will be instrumental in refining the therapeutic paradigm for ROS1+ NSCLC, with the ultimate goal of improving long-term survival and quality of life for affected patients.

Table 2:

Summary of safety and tolerability outcomes of taletrectinib

Safety Outcome	Frequency/Severity	Notes/Details	References
Gastrointestinal AEs	88% (any grade); mostly grade 1	Diarrhea, nausea, vomiting; dose reductions infrequent	[22], [42], [55], [56]
Elevated AST	72–76% (any grade); mostly grade 1	Mild, reversible; rarely led to discontinuation	[22], [56]
Elevated ALT	68% (any grade); mostly grade 1	Mild, reversible; rarely led to discontinuation	[22], [56]
Neurologic AEs	Dizziness: 21–23% (mostly grade 1); Dysgeusia: 10–15% (mostly grade 1)	No severe CNS toxicity; low rates compared to other ROS1 TKIs	[55]
Discontinuation due to AEs	5–6.5%	Low rate; most patients able to continue therapy	[22], [56]
Dose reduction due to AEs	19%	Most common for GI or hepatic events	[23], [24]
Serious AEs (SAEs)	Rare	Hepatotoxicity, ILD/pneumonitis, QTc prolongation, hyperuricemia, CPK elevation, fractures, embryo-fetal toxicity (warnings/precautions)	[5]
Grade 3/4 AEs	Uncommon	Most events were grade 1–2	[23], [24]
Other AEs	Myalgia, skeletal fractures, hyperuricemia (rare)	Included in FDA warnings/precautions	[12]

Table 3:

Comparing the efficacy of taletrectinib with other competing ROS1 tyrosine kinase inhibitors in the treatment of ROS1 fusion–positive non-small cell lung cancer

Drug	FDA Approval for ROS1+ NSCLC	Recommended Dose	ORR (TKI-naïve)	ORR (TKI-pretreated)	CNS Activity	G2032R Mutation Activity	References
Taletrectinib	Yes	600 mg QD, fasting	88.8–91%	52–55.8%	High	Yes (61–67%)	[21], [23], [27]
Crizotinib	Yes	250 mg BID	71–72%	N/A	Low	No	[8], [9], [19], [49], [50]
Entrectinib	Yes	600 mg QD	67–81%	<20%	Moderate	No	[3], [17], [47]
Lorlatinib	No (ALK+ only)	100 mg QD	62%	35%	High	Minimal (0–10%)	[6], [35], [54]
Repotrectinib	Yes	160 mg QD ×14d, then BID	79%	38%	High	Yes (59–67%)	[38], [39], [40]

Table 4:

Comparative safety and tolerability profile of taletrectinib versus other ROS1 TKIs in ROS1 fusion–positive NSCLC, based on head-to-head or indirect clinical trial data

Drug	Most Common AEs (≥20%)	Grade 3–4 AE Rate	Neurologic AEs (any grade)	Hepatotoxicity (AST/ALT↑)	GI AEs (any grade)	Discontinuation Due to AEs	Distinctive Toxicities	References
Taletrectinib	Diarrhea, nausea, vomiting, AST↑, ALT↑	6–7%	Dizziness 21–23%, dysgeusia 10–15% (mostly grade 1)	AST 72–76%, ALT 68% (mostly grade 1)	88%	5–6.5%	Low neurotoxicity, rare ILD, rare QTc prolongation	[21], [23], [27]
Crizotinib	Visual disturbance, diarrhea, nausea, vomiting, edema	18.7%	Visual disturbance 82%, dizziness 22%	AST 14–16%, ALT 11–13% (mostly grade 1–2)	60–70%	<5%	Visual AEs, edema, rare ILD	[8], [9], [19], [49], [50]
Entrectinib	Fatigue, weight gain, constipation, dizziness, dysgeusia	34%	Dizziness 46%, dysgeusia 43%, cognitive 23%	AST 16%, ALT 13% (grade 3–4: 23%)	60–70%	4–5%	CNS AEs, weight gain, rare CHF	[3], [17], [47]
Lorlatinib	Hypercholesterolemia, hypertriglyceridemia, edema, cognitive/mood changes	39%	Cognitive 23%, mood 21%, peripheral neuropathy 39%	AST 8%, ALT 6% (grade 3–4: 1–2%)	30–40%	7%	Hyperlipidemia, CNS AEs, edema	[6], [35], [54]
Repotrectinib	Dizziness, dysgeusia, paresthesia, constipation, fatigue	29%	Dizziness 58%, dysgeusia 50%, paresthesia 30%	AST 13%, ALT 10% (grade 3–4: 2–3%)	50–60%	3%	Neuropathy, ataxia, low discontinuation	[38], [39], [40]

Article Highlights.

• ROS1 fusion–positive NSCLC is a rare molecular subset (1–2% of cases) characterized by high rates of CNS involvement and resistance to first-generation TKIs.

• Taletrectinib is a next-generation ROS1 inhibitor with potent systemic and intracranial activity, engineered to overcome key resistance mutations, including G2032R.

• Clinical trials (TRUST-I and TRUST-II) demonstrated high response rates in both TKI-naïve (88.8%) and TKI-pretreated (55.8%) patients, with durable responses and strong intracranial efficacy.

• The safety profile is favorable, with predominantly low-grade gastrointestinal and hepatic events and a low incidence of neurologic toxicity compared to other ROS1 inhibitors.

• The June 2025 FDA approval of taletrectinib provides an important new option for patients with advanced ROS1+ NSCLC, addressing major limitations of earlier therapies.

• Ongoing challenges include resistance mechanisms such as L2086F, limited global regulatory approvals, and the absence of phase III confirmatory trials.

• Future priorities include optimizing sequencing strategies for ROS1 inhibitors, expanding access to molecular diagnostics, and exploring combination approaches to delay resistance.